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Abstract
Background: Drug addiction is a complex and chronic mental disease, which places a large burden on the
American healthcare system due to its negative effects on patients and their families. Recently, network
pharmacology is emerging as a promising approach to drug discovery by integrating network biology and
polypharmacology, allowing for a deeper understanding of molecular mechanisms of drug actions at the systems
level. This study seeks to apply this approach for investigation of illicit drugs and their targets in order to elucidate
their interaction patterns and potential secondary drugs that can aid future research and clinical care.
Results: In this study, we extracted 188 illicit substances and their related information from the DrugBank
database. The data process revealed 86 illicit drugs targeting a total of 73 unique human genes, which forms an
illicit drug-target network. Compared to the full drug-target network from DrugBank, illicit drugs and their target
genes tend to cluster together and form four subnetworks, corresponding to four major medication categories:
depressants, stimulants, analgesics, and steroids. External analysis of Anatomical Therapeutic Chemical (ATC) second
sublevel classifications confirmed that the illicit drugs have neurological functions or act via mechanisms of
stimulants, opioids, and steroids. To further explore other drugs potentially having associations with illicit drugs, we
constructed an illicit-extended drug-target network by adding the drugs that have the same target(s) as illicit drugs
to the illicit drug-target network. After analyzing the degree and betweenness of the network, we identified hubs
and bridge nodes, which might play important roles in the development and treatment of drug addiction. Among
them, 49 non-illicit drugs might have potential to be used to treat addiction or have addictive effects, including
some results that are supported by previous studies.
Conclusions: This study presents the first systematic review of the network characteristics of illicit drugs, their
targets, and other drugs that share the targets of these illicit drugs. The results, though preliminary, provide some
novel insights into the molecular mechanisms of drug addiction. The observation of illicit-related drugs, with partial
verification from previous studies, demonstrated that the network-assisted approach is promising for the
identification of drug repositioning.
Background
Drug addiction is a complex and chronic mental disease
characterized by compulsive drug seeking and use despite
its harmful consequences. It places a large burden on the
American healthcare system due to the detrimental
effects of this disease and associated drug use on patients
and their families. Abuse and addiction to illicit drugs
leads to increased rates of illness [1] and emergency
room treatment [2,3]. Additionally, substance abuse rates
are higher in patients with psychiatric illness (e.g., schizo-
phrenia), which leads to an increase in the risk of violent
and aggressive behavior [4].
Over the last few decades, investigators studying addic-
tion behavior have identified numerous genetic and envir-
onmental factors that contribute to the development of
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addiction. Twin and familial studies have suggested that
the genetic factors account for 30-60% of the overall risk
for the development of drug addiction [5]. This genetic
involvement has been shown to be polygenic, which
involves multiple genes that might cooperate through
numerous pathways [6]. In addition to addiction, many
psychiatric ailments related to illicit drug use are also
polygenic and have complex genetic causes [7]. Much of
the research on addiction has been general or focused on
only one individual drug but not on a category of drugs.
Familial analyses [8,9] and literature reviews [10,11] have
been the primary drivers of research in this domain. As
pharmaceuticals are and will continue to be a driver of
care for addiction and other related psychiatric illness,
further work is needed to focus on addiction from the
perspective of the illicit substances and medications used
to treat the addictive effects [12]. Due to the genetic
complexity of addiction and the numerous types of addic-
tive substances, we hypothesize that a large-scale analysis
of multiple illicit drugs and their target genes can provide
a broader understanding of substance abuse.
Recently, network pharmacology approaches have
been utilized to transition drug discovery techniques
from developing ligands for single targets to more clini-
cally efficacious drugs that target multiple proteins
[13-17]. Application of these concepts in the investiga-
tion of the drugs range from target identification and
side effect prediction [18] to analyses of protein interac-
tions and molecular transport [5]. These studies help
researchers and clinicians understand molecular
mechanisms, treatment indications, and side effects of
antipsychotic medications and, thus, network pharma-
cology has become a new paradigm in drug discovery
[19,20]. In the drug-target interaction networks, nodes
can represent drugs, diseases, targets, and proteins while
the edges represent physical interactions and regulations
between nodes. Network-based approaches might be
vital in understanding the genetics and substances
involved in addiction. However, this approach relies
upon a complete set of drug and drug target data.
Recently, DrugBank, a publicly available database, has
provided a comprehensive set of literature-extracted
bioinformatics and cheminformatics data [21-23], which
makes it possible to study all addiction-related drugs
and their targets at the systems level.
In this study, we extended our previous, preliminary
work [24] and applied network pharmacology approaches
for analysis of illicit drugs and their targets to further
understand the relationships between the various addic-
tive substances and their targets. To identify drugs that
have the potential to cause addictive effects or be used to
treat addiction, we further explored the drugs that have
common targets with illicit drugs in the context of drug-
target networks. This work is novel because it is first to
apply a network-based approach to revealing the relation-
ship between illicit drugs and their targets in order to
better understand the processes of addiction. Moreover,
this network analysis could identify some important tar-
gets and drugs, which might enhance the development of
treatment strategies for addiction.
Materials and methods
Drugs and their corresponding targets
To obtain information on drugs and their targets, we
accessed the XML drug data from DrugBank (version
3.0) [25], which includes 6712 drugs and 150 data fields
for each drug. Half of this information from DrugBank
is devoted to drug/chemical data and the other half is
devoted to drug target or protein data. It is one of the
most comprehensive repositories of biochemical and
genetic information for drugs from peer-reviewed litera-
ture. The detailed information on drugs and their tar-
gets allows for systems analyses of multiple drugs and
their targets simultaneously at the molecular level.
In this study, we focused specifically on illicit drugs
and selected those drugs with “illicit” annotation in the
“Group” field. In DrugBank, the “Group” field represents
the legal status of a drug while “Category” represents
the specific class of the medication based on therapeutic
characteristics. For each drug, we extracted information
from the following fields: “Name,” “Accession Number,”
“Groups,” “Categories,” “ATC Codes,” and “Targets.” In
the “Targets” field, the data contains drug targets to
which a drug can bind, including proteins, macromole-
cules, nucleic acids, or small molecules. We only
extracted human proteins with UniProtKB identifiers
and then mapped them to Entrez gene symbols and IDs
by using the UniProt ID Mapping service [26]. To inves-
tigate if some non-illicit drugs might have addictive
effects or could be used to treat addiction, we further
collected a set of non-illicit drugs that share at least one
common target with at least one illicit drug. The set of
drugs were grouped as illicit-related drugs. For the pur-
pose of comparison, we also collected a set of all
approved medications with targets and their targets in
DrugBank. After excluding illicit drugs and illicit-related
drugs, we grouped the remaining drugs as “other drugs.”
Therefore, we utilized four sets of drugs: illicit drugs,
illicit-related drugs, other drugs, and all drugs.
To further examine the classification characteristics of
illicit drugs and illicit-related drugs compared to other
drugs, we utilized the Anatomical Therapeutic Chemical
(ATC) classification system [27]. The ATC system is
controlled by the WHO Collaborating Centre for Drug
Statistics Methodology. The system groups active drugs
into five different levels according to the organ or sys-
tem on which they act as well as their therapeutic and
chemical characteristics. The first level of the ATC
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classification has fourteen anatomical main groups, of
which each is represented by one letter. For example, N
represents “nervous system.” The second sublevel of the
ATC coding system contains systems-specific therapeu-
tic subgroups represented by a two-digit number. For
example, N05 represents “psycholeptics,” a therapeutic
subgroup of the anatomical group N “nervous system.”
In this study, we utilized the second sublevels of drug
classification.
To compare the ATC classification characteristics of
the two sets of drugs (illicit drugs or illicit-related drugs)
to other drugs, we performed Fisher’s exact test for each
drug ATC second sublevel category. It should be noted
that other drugs are defined as all drugs having at least
one target from DrugBank and excluding illicit drugs and
illicit-related drugs. For each drug category, we con-
structed a 2 × 2 contingency table, which includes four
counts: where is the number of illicit
drugs or illicit-related drugs in the category, is the
number of other drugs belonging to the category, is the
number of illicit drugs or illicit-related drugs not belong-
ing to the category, and is the number of other drugs
not belonging to this category. Therefore, for each ATC
second sublevel category, we calculated one p-value and
then chose the ATC second sublevel with a p-value that
was less than 0.05 as the significant category compared
to other drugs with targets.
Functional analysis
To characterize the functionality of drugs’ target genes,
we performed Gene Ontology (GO) Slim Classification
and Kyoto Encyclopedia of Genes and Genomes
(KEGG) enrichment analyses of drugs’ target genes by
using the Web-Based Gene Set Analysis Toolkit (Web-
Gestalt) [28]. For GO Slim Classification analysis, Web-
Gestalt maps a set of genes to a cut-down version of the
GO terms and counts numbers of the interest genes
existing in the corresponding gene set of a given GO
Slim term. We first input the illicit drugs’ target genes
and non-illicit drugs’ target genes into WebGestalt,
respectively, to obtain the numbers of genes observed in
each category and then conducted Fisher’s exact test.
Here, we performed the enrichment analysis using
terms from two GO domains: Biological Process (BP)
and Molecular Function (MF). For KEGG pathway ana-
lysis, WebGestalt overlays a set of genes to human
KEGG pathways via statistical test to identify the path-
ways enriched with the drugs’ target genes. WebGestalt
applies a hypergeometric test followed by correction of
Benjamini-Hochberg method to reduce type I error,
thus, it calculates adjusted p-values after multiple test
correction [29]. In this study, we applied an adjusted p-
value cutoff 0.05 to define KEGG pathways that are sig-
nificantly enriched with illicit drugs’ target genes or
non-illicit drugs’ target genes, and then performed Fish-
er’s exact test for statistical significance.
To compare these GO Slim terms and enriched KEGG
pathways for illicit drugs’ target genes with those of all
non-illicit drugs’ target genes, we adopted a design simi-
lar to a specific statistical test above, i.e., Fisher’s exact
test. For each GO Slim term or KEGG pathway, we con-
structed a 2 × 2 contingency table, which includes four
counts: where is the number of drug
target genes in the GO Slim term or KEGG pathway,
is the number of other drug target genes in the Drug-
Bank belonging to the same GO Slim term or KEGG
pathway, is the number of illicit drug target genes not
belonging to the GO Slim term or KEGG pathway, and
is the number of other drug targets that not belonging to
the GO Slim term or KEGG pathway. Therefore, for each
GO Slim term or KEGG pathway, we calculated one
p-value and chose the GO Slim term or KEGG pathway
with a p-value that was less than 0.05 as the significant
GO Slim term or KEGG pathway.
Network analysis
In our drug-target networks, the nodes are drugs and
target genes while the edges represent the interactions
between drugs and their targets. Based on the sets of
drugs and their target genes collected above, we built
three drug-target networks: 1) an illicit drug-target net-
work, which includes illicit drugs and their target genes;
2) an illicit-extended drug-target network, including illi-
cit drugs, illicit drugs’ targets, and illicit-related drugs;
3) a full drug-target network including illicit drugs, non-
illicit drugs, and their targets from DrugBank.
Nodes that act as hubs in subnetwork or bridging
nodes among subnetworks might play critical roles in
drug actions [13]. Node degree, the number of edges
linked to a node, is a basic but informative measure of
networks’ characteristics [30]. Nodes with higher degree
are referred to hubs, suggesting their critical roles in the
network. To identify hubs, we first calculated the degree
of each node and then plotted the degree of all nodes.
Based on this degree distribution, the point where the
distribution begins to reach its asymptote is detected.
The nodes, including drugs and genes, with a degree
higher than the detected point are considered hubs.
Bridge nodes can be assessed and determined by calcu-
lating the betweenness centrality. Betweenness can mea-
sure how signals travel through the interaction network,
with high betweenness reflecting multiple paths between
nodes and low betweenness indicating few paths [31]. For
a given node , its betweenness is defined as the sum, for
each pair of nodes in the network, of the ratio
between the number of shortest paths from to passing
through and the total number of shortest paths from
to . This betweenness calculation is represented
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mathematically for a given node as ,
where represents the number of shortest paths from
node to node and represents the number of
shortest paths from node to node that also pass through
node . To identify the bridge nodes based on the
betweenness, we adopted the method above used to deter-
mine hubs. We first calculated the betweenness using
algorithms implemented in the Cytoscape plugin cyto-
Hubba (v. 1.6) [32] and then drew the betweenness distri-
bution to find the point that the distribution begins to
reach its asymptote. The nodes, including drugs and
genes, with a betweenness higher than the detected point
were regarded as bridge nodes.
The networks were visualized by the software Cytoscape,
an open source network analysis platform [33].
Results
Illicit drugs and their targets
We obtained 188 illicit drugs according to the “illicit”
status annotated by DrugBank. Those illicit drugs can
be grouped into 60 categories according to DrugBank
category annotation. The top 10 categories of these
medications are opioid analgesics (number of drugs: 24),
hypnotics and sedatives (24), narcotics (21), anti-anxiety
agents (19), GABA modulators (15), analgesics (13), hal-
lucinogens (12), benzodiazepines (11), anticonvulsants
(10), and central nervous system stimulants (10). These
categories indicate that the illicit drugs have the poten-
tial for strong neurologic impact.
Among the 188 illicit drugs, only 86 (45.7%) have
unique human protein targets, which can be mapped to
73 unique human genes. We applied the GO Slim Classifi-
cation tool implemented in the WebGestalt to examine
the number distribution of the 73 illicit drugs’ target
genes among each GO Slim term as compared to that
among the 1235 non-illicit drugs’ target genes. We tested
GO Slim terms in two GO domains: Biological Process
and Molecular Function. For each GO Slim term, we per-
formed a Fisher’s exact test and then applied a cutoff
p-value of 0.05 to identify GO Slim terms enriched in a
set of target genes. We identified seven GO Slim terms
that are significantly enriched in the illicit target genes
(Table 1). Most of them are directly related to molecular
transduction, transporter activity, and ion binding. It
should be noted that most of the non-illicit drugs’ target
genes (902, 73.0%) are involved in “metabolic process,”
which is much higher than the percentage of illicit drugs’
target genes (33, 45.2%) in that category. Additionally,
some GO Slim terms such as “nucleotide binding,”
“hydrolase activity,” and “transferase activity” comprise
approximately 15-20% of the non-illicit drugs’ target genes
but jointly have only one illicit drugs’ target gene. These
results indicate that, compared to non-illicit drugs’ target
genes, the illicit drugs’ target genes tend to be involved in
the receptor process and signaling transduction.
Pathway enrichment analyses were further conducted
to identify over-represented canonical biological pathways
among the illicit drugs’ target genes compared to the
other drugs’ target genes. Using WebGestalt, nineteen
KEGG pathways were identified as being significantly
enriched with the 73 illicit drugs’ target genes and
163 significant pathways enriched with the non-illicit
drugs’ target genes (adjusted p-value < 0.05). Then we
performed the Fisher’s exact test by comparing illicit and
other drugs’ target genes for each of the nineteen KEGG
pathways (Additional file 1). Four KEGG pathways were
identified as being significantly enriched in the illicit
drugs’ target genes. They are “neuroactive ligand-recep-
tor” (Fisher’s exact test, p-value = 2.2 × 10-16), “calcium
signaling pathway” (p-value = 2.8 × 10-4), “amyotrophic
lateral sclerosis” (p-value = 2.9 × 10-3), and “long-term
potentiation” (p-value = 2.9 × 10-3). As expected, except
for the “calcium signaling pathway,” all other three path-
ways are directly related to neurodevelopment, which is
consistent to the neuroscience theories of drug addiction.
And calcium signaling has been studied with their roles
in the pathogenesis of neurodevelopmental disorders.
Illicit drug-target network
To investigate the organization and association between
the illicit drugs and their targets, we first constructed an
illicit drug-target network by compiling the associations
between illicit drugs and their targets. For comparison
purpose, we built a full drug-target network that
included all drugs (illicit and non-illicit drugs), and their
targets from DrugBank.
The illicit drug-target network has 159 nodes (86 illicit
drugs and 73 target genes) and 563 edges (Additional
file 2). After superimposing the DrugBank categories on
the network, four topological subnetworks were identi-
fied in correspondence with four major medication cate-
gories: depressants (benzodiazepines and barbiturates),
stimulants (amphetamines, hallucinogens), analgesics,
and steroids (Figure 1). To further assess the classifica-
tion characteristics of these drugs, we compared the
ATC therapeutic second sublevels for the illicit and
other drugs using Fisher’s exact test. Among the 86 illi-
cit drugs, 50 drugs have at least one ATC second suble-
vel classifications. And among the 773 other drugs, 594
drugs have at least one ATC second sublevel classifica-
tion. We found that those drugs are over-represented in
seven ATC second sublevel categories (Table 2). As
expected, five of seven ATC categories belong to the
nervous system and the most significant ATC category
is psycholeptics (N05).
The full drug-target network includes 2619 nodes (1286
drugs and 1333 target genes) and 5098 edges
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(Additional file 3). In the illicit drug-target network, 86
illicit drugs have an average of 6.6 targets (range: 1 ~
20) while 73 target genes are targeted by 7.7 drugs on
average (range: 1 ~ 29). In the full drug-target network,
drugs have an average of 4.0 targets (range: 1 ~ 144)
while targets are targeted by an average of 3.8 drugs
(range: 1 to 76). Thus, both drug degree (number of tar-
gets) and target degree (number of drugs) in the illicit
drug-target network are significantly higher than those
of the full drug-target networks (Wilcoxon rank-sum
test p-values for drug degree and target degree: 6.0 ×
10-4 and 2.4 × 10-7, respectively). This comparison
reveals that, relative to all drug-target networks, the illi-
cit drugs and targets tend to be strongly connected and
form tight clusters (Additional file 4), which is consis-
tent with the previous result showing that neurological
drugs cluster together [34].
Using degree distribution methods, we pinpointed the
nodes with a degree greater than eight as hubs for both
the illicit drug-target network and full drug-target network
(Additional file 5). Thus, in the illicit drug-target network,
26 drugs (30.2%) and 25 targets (34.2%) are hubs, while in
the full drug-target network, 145 drugs (11.3%) and 121
targets (9.1%) are hubs (Figure 2). The proportion of hubs
in the illicit drug-target network is higher than that in the
full drug-target network, which is consistent with our
above described results of average degree.
Of the 26 hub drugs in the illicit drug-target network,
25 belong to the cluster of depressants (alprazolam,
amobarbital, aprobarbital, barbital, barbituric acid deri-
vative, bromazepam, butabarbital, butalbital, butethal,
chlordiazepoxide, clobazam, clonazepam, clorazepate,
clotiazepam, diazepam, estazolam, ethchlorvynol, fludia-
zepam, flurazepam, halazepam, midazolam, prazepam,
quazepam, talbutal, triazolam) while the other hub drug
is methamphetamine. This distribution indicates that
the hub drugs belong to similar categories and act via
common mechanisms. Among the 26 drugs, 23 belong
to psycholeptics (N05), one belong to antiepileptic
(N03), and two (butabarbital and butalbital) do not have
an ATC code. Among the 23 psycholeptics, thirteen are
hypnotics and sedatives (N05C) while the other ten
drugs are anxiolytics (N05B).
Remarkably, among the 25 hub target genes, nineteen
belong to the gamma-aminobutyric acid receptors
(GABRs) and act as hubs in the cluster of depressants.
They are GABRA1, GABRA2, GABRA3, GABRA4,
GABRA5, GABRA6, GABRB1, GABRB2, GABRB3,
GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP,
GABRQ, GABRR1, GABRR2, and GABRR3. Three opioid
receptors (OPRD1, OPRK1, and OPRM1) act as hubs for
analgesic pharmaceuticals. Three adrenergic transporters
(SLC6A2, SLC6A3, and SLC6A4) act as hubs in the clus-
ter of amphetamine stimulants. These results indicate
that those genes play important roles in the molecular
mechanisms of drug addiction development for their cor-
responding drug categories.
Illicit-extended drug-target network
To identify some medications that might have associa-
tions with illicit drugs, we explored a set of illicit-related
drugs that share at least one common target with at
least one illicit drug. Those drugs could have novel
potential in treating or modulating drug addiction and
other psychiatric ailments or might have addictive
effects due to their shared set of targets. Based on their
interactions with illicit drugs’ targets, we added these
illicit-related drugs to the illicit drug-target network to
build an illicit-extended drug-target network. The illicit-
extended drug-target network includes 586 nodes and
1725 edges (Additional file 6). The 586 nodes include 86
illicit drugs, 427 illicit-related drugs, and 73 illicit drugs’
target genes. The average drug degree (number of target
genes) is 3.4 (range: 1~20) while the average target
degree (number of drugs) is 23.6 (range: 1:74). These
degrees are not comparable to those of the illicit drug-
target network due to the relative oversaturation of drug
nodes as compared to gene nodes.
Table 1 Gene Ontology (GO) terms significantly enriched in illicit drugs’ target genes compared to non-illicit drugs’
target genes in the full drug-target network
GO ID GO terma # of illicit drugs’ target genes (%b) # of non-illicit drugs’ target genes (%c) p-valued
GO:0060089 MF: Molecular transducer activity 55 (75.3) 281 (22.8) < 2.2 × 10-16
GO:0007154 BP: Cell communication 58 (79.5) 441 (35.7) 1.5 × 10-13
GO:0005215 MF: Transporter activity 38 (52.1) 215 (17.4) 9.9 × 10-11
GO:0065007 BP: Biological regulation 63 (86.3) 628 (50.9) 7.9 × 10-10
GO:0032501 BP: Multicellular organismal process 50 (68.5) 509 (41.2) 7.7 × 10-6
GO:0051179 BP: Localization 45 (61.6) 461 (37.3) 5.8 × 10-5
GO:0043167 MF: Ion binding 35 (47.9) 432 (35.0) 0.032
aGene Ontology domains: BP (biological process) and MF (molecular function).
bThe proportion of illicit drugs’ target genes belong to a given GO Slim term among the 73 illicit drugs’ target genes.
cThe proportion of non-illicit drugs’ target genes belong to a given GO Slim term among the 1235 non-illicit drugs’ target genes.
dp-value was calculated by Fisher’s exact test.
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Among the 427 illicit-related drugs, 365 have at least
one ATC second sublevel classification. Compared to 594
other drugs with ATC second sublevel classification, these
illicit-related drugs are significantly over-represented in 12
ATC second sublevel categories (Table 3). Among them,
five belong to the nervous systems (N), i.e., psycholeptics
(N05), psychoanaleptics (N06), anesthetics (N01), anti-
Parkinson drugs (N04), and other nervous system drugs
(N07). The others belong to the corticosteroids and der-
matological preparations (D07), sex hormones and modu-
lators of the genital system (G03), corticosteroids for
systemic use (H02), drugs for functional gastrointestinal
disorders (A03), vasoprotectives (C05), nasal preparations
(R01), and ophthalmologicals (S01) categories. Compared
to the ATC second sublevel categories that are over-
represented in the illicit drugs, the proportion of drugs
belonging to nervous systems in the illicit-related drugs
(171, 46.8%) is significantly lower than that of illicit drugs
(39, 78.0%) (Fisher’s exact test, p-value = 3.4 × 10-5).
These results revealed, though most of the illicit-related
drugs still belong to the nervous systems, they also involve
more drugs from other categories.
Figure 1 Illicit drug-target network. The illicit drug-target network consists of four major subnetworks corresponding to four major medication
categories: depressants, analgesics, steroids, and stimulants. There are three small (orphan) subnetworks located in the bottom of the figure.
Nodes in green correspond to illicit drugs and nodes in red correspond to target genes.
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Table 2 ATC second sublevel categories significantly enriched in illicit drugs compared to other drugsa
ATC code ATC therapeutic subgroup # of illicit drugs (%b) # of other drugs (%c) p-valued
N05 Psycholeptics 24 (48.0) 3 (0.5) 1.2 × 10-26
N01 Anesthetics 5 (10.0) 0 (0) 2.3 × 10-6
A08 Antiobesity preparations, excluding diet products 4 (8.0) 1 (0.2) 1.5 × 10-4
N02 Analgesics 6 (12.0) 11 (1.9) 1.0 × 10-3
A14 Anabolic agents for systemic use 2 (4.0) 0 (0) 5.9 × 10-3
N06 Psychoanaleptics 3 (6.0) 4 (0.7) 0.012
R05 Cough and cold preparations 2 (4.0) 1 (0.2) 0.017
aThe other drugs represent the drugs in the full drug-target network excluding illicit drugs and illicit-related drugs. Among those other drugs, 594 have ATC
second sublevel classifications.
bThe proportion of illicit drugs belong to a given ATC category among the 50 illicit drugs with ATC second sublevel classifications.
cThe proportion of other drugs belong to a given ATC category among the 594 other drugs with ATC second sublevel classifications.
dp-value was calculated by Fisher’s exact test.
Figure 2 Distribution of drugs (top panel) and drug’s targets (bottom panel) by their interaction degree in illicit drug-target network
(red) and the full drug-target network (blue). On the top panel, it shows the proportion of drug (Y-axis) measured by their degree of
interactions (number of targets) (X-axis) in the network. On the bottom panel, it shows the proportion of targets (Y-axis) measured by their
degree of interactions (number of drugs) (X-axis) in the network.
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The nodes in the illicit-extended drug-target network
with degrees greater than eight are defined as hubs,
according to the degree distribution methodology. Of
the 427 illicit-related drugs in the network, 26 are hubs
(Figure 3). Among the 26 drugs, 22 have ATC classifica-
tions. While all 22 drugs belong to the main nervous
system (N) category, they have a more diverse range of
therapeutic subgroups. For example, fifteen are psycho-
leptics (N05), three are antiepileptics (N03), two are
anti-Parkinson (N04), and two others are psychoanalep-
tics (N06). Among the 73 target genes, 52 have their
degrees greater than eight. This is primarily due to the
relative oversaturation of drugs in the illicit-extended
drug-target network. In addition to the 25 genes that
already are hubs in the illicit drug-target network, an
additional 27 genes act as hubs because of the inclusion
of targeting non-illicit drugs. For example, gene
CHRM1is targeted by one illicit drug and 71 non-illicit
drugs. Other examples include DRD2 (number of illicit
drugs: 1; number of non-illicit drugs: 62), CHRM2
(number of illicit drugs: 1; number of non-illicit drugs:
59), NR3C1 (number of illicit drugs: 1; number of non-
illicit drugs: 37), and ADRA2B (number of illicit drugs:
1; number of non-illicit drugs: 31).
In addition to identifying hubs, we also sought out
bridge nodes by computing a betweenness value for
each node in the illicit-extended drug-target network.
To categorize bridge nodes, we used a method similar
to the degree distribution and assessed betweenness
values by their rank (Additional file 7). We determined
that a node with the betweenness value greater than
2000 as bridge nodes. There are 51 bridge nodes (Figure
4), in which 25 belong to drugs and 26 belong to target
genes. Among the 25 drug bridge nodes, only two exist
in the 26 drug hubs. Thus, we identified 49 drugs that
might have high potentials for addiction effects or effi-
cient treatment of addiction. Among the 73 target
genes, 24 act as bridge nodes. Among them, gene ESR1
links the cluster of analgesics to the cluster steroids and
gene GABRA1 links the cluster of depressants to the
cluster stimulants.
Discussion
In this study, we explored the relationships among illicit
drugs, illicit-related drugs, and their targets in the con-
text of networks in order to further understand the
molecular mechanisms of addiction. We presented a
systematic method for studying illicit drugs and their
targets, even for those non-illicit drugs that share com-
mon targets with illicit drugs. Furthermore, we have
shown that network topological analyses used to identify
important nodes could serve as a basic tool for knowl-
edge discovery.
One important output of this study is the illicit drug-
target network. Though the network is not very complex,
its clustering can capture a drug classification pattern,
which provides evidence that the network pharmacology
approach is effective and executable to investigate medi-
cations and their targets. In the network, the 86 illicit
drugs with 73 target genes tend to cluster together, form-
ing four subnetworks corresponding to four medication
groups: depressants, stimulants, analgesics, and steroids.
Further external analysis of ATC codes confirmed that
the illicit drugs have neurological functions or act via
mechanisms of stimulants, opioids, and steroids.
Another important application of network analysis
in this study is to recruit the non-illicit drugs into the
illicit drug-target network, which demonstrates the
Table 3 ATC second sublevel categories significantly enriched in illicit-related drugs compared to other drugsa
ATC code ATC therapeutic subgroup # of illicit-related drugs (%b) # of other drugs (%c) p-value
N05 Psycholeptics 54 (14.8) 3 (0.5) 1.4 × 10-20
N06 Psychoanaleptics 38 (10.4) 4 (0.7) 6.7 × 10-13
N01 Anesthetics 25 (6.9) 0 (0) 1.9 × 10-11
D07 Corticosteroids, dermatological preparations 23 (6.3) 0 (0) 1.4 × 10-10
N04 Anti-Parkinson drugs 17 (4.7) 2 (0.3) 4.2 × 10-6
G03 Sex hormones and modulators of the genital system 21 (5.8) 5 (0.8) 1.1 × 10-5
H02 Corticosteroids for systemic use 12 (3.3) 1 (0.2) 7.0 × 10-5
N07 Other nervous system drugs 14 (3.8) 5 (0.8) 2.9 × 10-3
A03 Drugs for functional gastrointestinal disorders 14 (3.8) 5 (0.8) 2.9 × 10-3
C05 Vasoprotectives 12 (3.3) 4 (0.7) 3.2 × 10-3
R01 Nasal preparations 16 (4.4) 7 (1.2) 3.6 × 10-3
S01 Ophthalmologicals 43 (11.8) 44 (7.4) 0.027
aThe other drugs represent the drugs in the full drug-target network excluding illicit drugs and illicit-related drugs. Among those other drugs, 594 have ATC
second sublevel classifications.
bThe proportion of illicit drugs belong to a given ATC category among the 365 illicit-related drugs with ATC second sublevel classifications.
cThe proportion of other drugs belong to a given ATC category among the 594 other drugs.
dp-value was calculated by Fisher’s exact test.
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identification of potential drug repositioning using net-
work analysis [35]. Due to the disjointed nature of the
subnetworks and the relative skew of hub nodes in the
depressants subnetwork, an extended network is neces-
sary to identify further modulators of addiction. The illi-
cit drug network was extended by including all illicit
and non-illicit drugs that targeted any illicit drugs’ tar-
get. As a result, the network was oversaturated with
pharmaceuticals and this step allowed for new connec-
tions between subnetworks and an improvement in the
possibility of identifying important drugs that modulate
similar sets of genes upon which illicit drugs act. Most
of the illicit-related drugs in this network have some
neurological function or act through a steroid or neuro-
transmitter mechanism. The power of this extended net-
work is to identify the hub and bridge nodes that might
play important roles for addiction development or treat-
ments. For example, naloxone, the strongest drug bridge
node, is an opioid inverse agonist which is used to treat
opioid overdoses and counteract emergent depressant of
vital functions [36,37]. The opioid receptor OPRK1, the
third strongest bridge node, has been investigated as a
potential target in the treatment of drug addiction, pos-
sibly via dynorphin [38-40]. The seventh strongest
bridge node, glucocorticoid receptor NR3C1, has been
studied as a possible neuroendocrine mediator of stress
and addiction response [41,42]. Aripiprazole, a hub, is
frequently used to treat methamphetamine abuse [43]
and alcohol dependence abuse [44] and bromocriptine,
another hub, is used in the treatment of cocaine addic-
tion [45]. It is also interesting to observe that some
nodes that connect various subnetworks. For example,
l-glutamic acid, ethanol, halothane, dihydrogenotoxine,
amoxapine, ginko biloba, quinidine barbiturate, SLC6A2,
and GRIN3A connect the clusters of depressants and
stimulants. Amitriptyline, mirtazapine, tramadol, meper-
idine, methadone, HTR2C, and HTR2A, ADRA2A con-
nect the analgesics and stimulants. The depressants and
Figure 3 Illicit-extended drug-target network, highlighted with hubs. Nodes with readable labels are hubs, which were defined by their
degrees being greater than eight. Rectangular nodes in green correspond to illicit drugs, triangular nodes in green correspond to illicit-related
drugs, and circle nodes in red correspond to target genes. Red edges represent the interactions between illicit drugs and their target genes
and grey edges represent the interactions between illicit-related drugs and their target genes that are also targeted by illicit drugs. Font size
corresponds to the degree of interactions.
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analgesics are interestingly connected via nodes in the
analgesics, stimulants, and depressants. Finally, naloxone
and ESR1 connect the analgesics to the steroids. These
connection patterns could help focus future research
based on the important nodes identified through this
type of systematic analysis.
Recently, Li and Burmeister [5] compiled 62 candidate
genes associated with at least one drug addiction based
on verified genetic evidence. Among the candidate genes,
47 have been targeted by at least one of the 1286 drugs
and 17 have been targeted by at least one of the illicit
drugs. Thus, comparing the 1333 genes targeted by these
1286 drugs, Li and Burmeister’s gene set is significantly
enriched in the illicit drug-target network (hypergeo-
metric test, p-value = 3.9 × 10-11). This finding illustrates
another link between genetic factors and drugs’ targets in
addiction development. Additionally, among the 17 genes,
five (GABRA2, OPRD1, OPRK1, OPRM1, and SLC6A2)
are hubs, which indicates that proteins vital to the media-
tion of neurological function such as GABA receptors,
opioid receptors, and adrenergic transporters act as the
main hub genes of the illicit drug network.
In this study, we extracted the interaction data between
drugs and their targets mainly from DrugBank. Though
the study provides a systematic review of relationships
among illicit drugs, their targets, and illicit-related drugs,
it still needs to be improved since the current data uti-
lized in this study is neither complete nor error- or bias-
free. For example, among 188 illicit drugs, only 86 drugs
have protein-coding targets. This indicates that further
investigation is needed to illustrate the molecular
mechanisms of drug addiction. Future research in this
area should include more drug-target information from
multiple target-centered databases such as Matador and
SuperTarget [46] and the Therapeutic Target Database
(TTD) [47,48]. Additionally, a large volume of genome-
wide molecular neuropharmacology data, such as micro-
array gene expression, genome-wide association studies,
and next-generation sequencing data, is available, and
much more data will become available in the near future
due to the rapid advances in high throughput technolo-
gies and the strong efforts supported by National Insti-
tutes of Health, numerous other foundations, and
pharmaceutical industry. Therefore, it is possible and
necessary to develop novel methods for multi-dimen-
sional data integration at the network and pathway levels,
and beyond, so that these studies will improve the accu-
racy and coverage of identification of drug’s target nodes
Figure 4 Illicit-extended drug-target network, highlighted with bridge nodes. Nodes with readable labels are bridge nodes, whose
betweenness value is greater than 2000. Font size corresponds to the betweenness value. Colors and shapes of nodes as well as colors of edges
are defined as in Figure 3.
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and drug nodes. To this end, novel subnetwork search
and module finding algorithm development and their
applications to this field is required. There are many net-
work algorithms available [49,50], which can be adopted
or enhanced for network pharmacology studies. In sum-
mary, the network pharmacology approach, combining
with multi-dimensional data, would allow researchers to
paint a more comprehensive view of addiction genetics
and identify a greater portion of interconnections
between drugs and genes.
Conclusion
This study is important because of the burden that
abused drugs place on individuals, their families, the
American healthcare system, and global health and soci-
etal influence. The emerging area of network pharma-
cology may be able to identify new treatments for
managing illicit drug abuse. However, more work is
necessary to identify common patterns to extract inter-
actions and influence treatment. Potential findings could
be used to inform treatment strategies based on patient
genetics, allow for secondary uses of drugs that have the
same targets, and improve treatments for drug addic-
tion, which in turn may aid psychiatric care and reduce
the burden on emergency rooms.
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